Can we please stop pretending that double-blind is remotely an option for psychedelic research. The purpose of subject blinding is that the subject will not know if they received the treatment so that both groups have equal placebo effect. Psilocybin is active in such a way that it is obvious to the subject if they received placebo or the treatment.
I'd really like to see a psilocybin study where they give one group psilocybin, give another group an active placebo, and ask them if they think they are in the psilocybin group or active placebo group. I imagine people guess correctly >90% of the time.
It's possible to do good medical science without double-blind. Pretending that you are doing double-blind when you actually are not just generates doubts in the methodology.
The mind is powerful.
Unfortunately this line of thinking doesn't hold up to scrutiny, and completely misses the forest for the trees. Mainly because the only implied alternative is to not blind subjects at all! How exactly would that reduce bias or otherwise improve the clinical trial design...?
> I imagine people guess correctly >90% of the time.
Yes in some cases you're right. Here's a paper from last year that does exactly what you asked [0]. They note that "Placebo could be distinguished well from active substance and correctly identified in 96% of the sessions." The placebos were ethanol and mannitol, for LSD and Psilocybin respectively.
The important takeaway is that subjects still had to guess. They didn't know their group assignment with certainty. And that is key to reducing bias.
I'd really like to see someone articulate a coherent alternative to subject blinding in psychedelic research.
Here are two ideas that I think are better than subject blinding for psychedelic research. I think the first one is the preferred method, but I think the second option is still better than using a placebo group or active placebo group.
* Have one group receive an established treatment and another group receive the psychedelic treatment. For psychedelic assisted therapy the comparison could be traditional therapies. I'm sure there are methods in the literature that promote increased creativity in subjects that could be used for this study.
* Double the treatment group. If you don't need to divide the subjects into multiple groups then you can put more subjects into the treatment group.
So yeah that's a light dose but definitely noticeable.
If there is an acceptable measure, why are psychedelics held to a different standard?
Not really true. "Medicinal doses" are typically a gram or less, unless a heroic dose (>3g) is somehow medicinal now. Under a gram the effects are pretty subtle with strains like Golden Teachers. If they're using Albino Penis Envy's then the effects could be a bit more pronounced, but really only to a regular psilocybin user. You could easily induce the yawning and giggliness via other drugs.
In research I mostly see dosages per kg, while responsible use wikis list absolute dosages (which matches my experience of user-weight not changing much of the perceived strength).
This seems natural to me since the brain does not grow with your weight and psychedelics unlike THC are not liposoluble AFAIK, but this is just me speculating and I have zero pharmaceutical-related education.
If it is weight-dependent what mechanism affects the strength?